Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections -

TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced positive results from a large prospective trial conducted for prevention of respiratory syncytial virus (RSV). The trial compared motavizumab, the investigational monoclonal antibody (MAb) also known as Numax(R), with Synagis(R) (palivizumab), the standard of care for preventing RSV hospitalization in high-risk infants. In the Phase 3 study involving 6,635 pre-term infants at high risk for RSV, with a primary endpoint of non- inferiority, motavizumab demonstrated overall 26-percent fewer RSV hospitalizations compared with Synagis (p<0.01 for non-inferiority). Additionally, motavizumab demonstrated a statistically significant 50 percent reduction in the incidence of RSV-specific medically attended outpatient lower respiratory infections (LRIs) (p<0.01) compared with Synagis. These findings were presented today in a poster entitled, Phase 3 Trial of Motavizumab, an Enhanced Potency RSV-Specific MAb for the Prevention of Serious RSV Disease in High-Risk Infants, at the Pediatric Academic Societies' Annual Meeting in Toronto, Canada.

"As RSV continues to be the leading cause of lower respiratory tract infections in infants in the United States, we are very encouraged by the results of this Phase 3 trial, which suggest that motavizumab may help to reduce the chance that our most vulnerable babies will have serious RSV disease," said Edward M. Connor, M.D., chief medical officer and executive vice president. "Data from the study showed that motavizumab was statistically superior to Synagis for the secondary endpoint of outpatient medically attended LRI caused by RSV, and thus may reduce the overall burden of RSV disease compared to the current stan
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/19/2014)... , Aug. 19, 2014  As power morcellator ... country, Bernstein Liebhard LLP notes that women in ... between a number of options that do not ... instrument. According to a report published by The ... these options include a mini-laparotomy and vaginal hysterectomy. ...
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim ... Administration (FDA) accepted for review the New Drug ... tiotropium and olodaterol delivered via the Respimat ® ... once-daily maintenance treatment of airflow obstruction in patients ... bronchitis and/or emphysema. Tiotropium + olodaterol FDC will ...
(Date:8/19/2014)...  SCILEX Pharmaceuticals, Inc., a company engaged in the ... treatment of pain, announced that it had formed a Scientific ... Gudin , Dr. Charles Argoff , Dr. ... SCILEX Chief Executive Officer Anthony ... greatly assist in the development and commercialization of future ...
Breaking Medicine Technology:As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4
... Corporation (Nasdaq: THOR ), a world leader in ... failing hearts, announced today that it has given notice of ... Convertible Notes due 2034 (CUSIP No. 885175AA7) (the "Notes") on ... 243,382 notes outstanding, which can be converted into 7.2 million ...
... Omeros Corporation (NASDAQ: OMER ), ... commercializing products focused on inflammation, bleeding and disorders ... outcome from its Phase 3 program evaluating OMS103HP ... reconstruction surgery.  OMS103HP did not meet the pre-specified ...
Cached Medicine Technology:Thoratec Corporation Announces Redemption of Senior Subordinated Convertible Notes Due 2034 2Thoratec Corporation Announces Redemption of Senior Subordinated Convertible Notes Due 2034 3Omeros Reports Outcome of Phase 3 Trials of OMS103HP 2Omeros Reports Outcome of Phase 3 Trials of OMS103HP 3
(Date:8/20/2014)... August 20, 2014 First Choice ... emergency rooms in the United States, named Richard Daniels, ... FM 685 facility. , “We are pleased to ... director of our second facility in Pflugerville,” said Dr. ... Emergency Room. , Dr. Daniels received his undergraduate ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 Kowa ... Expo West show to debut the new SL-17 portable ... a 20,000 lux white LED source controlled by an ... examination rooms. The SL-17 uses commercially available AAA rechargeable ... the previous SL-15 design requiring batteries designed specifically for ...
(Date:8/20/2014)... 2014 This agreement will allow ... defined networking, high availability cloud enablement, service, and ... while allowing OPEN-V to sell storageFOUNDRY’s expanding Nautilus ... work with OPEN-V on this distribution agreement of ... distribution channels at storageFOUNDRY. "Nautilus is a massively ...
(Date:8/19/2014)... August 20, 2014 Midtown Dentistry in Houston, ... dental office. All patients with cavities, or with old ... white fillings that can safely repair and restore teeth. , ... very latest materials, all of which are completely amalgam free. ... for use by the FDA for adults and children over ...
(Date:8/19/2014)... Top 10 Best SEO Hosting (Top10BestSEOHosting.com) has released its ... today and included in the list is Arvixe. , ... most outstanding suppliers on the list, beating out a number ... 10 Best SEO Hosting, Arvixe provides easy to use products ... Arvixe prides itself in providing web hosting with a rare ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2Health News:Top 10 Best SEO Hosting: Best Web Hosting Suppliers For 2014 Awarded to Arvixe 2
... A1c monitoring market is forecast to surpass $272 million by 2012. ... Other growth drivers include greater glucose control and product innovations that ... ... CA (PRWEB) October 28, 2008 -- World Health Organization forecasts global ...
... individual watching the stock market crash or a commuter ... journal Psychological Science, examines how stress affects ... more than young adults when under stress particularly ... how stress affects decision making, even though so many ...
... of Rochester psychologists to be published online Oct. 28 ... adds colorliterally and figurativelyto the age-old question of ... experiments, Andrew Elliot, professor of psychology, and Daniela Niesta, ... feel more amorous toward women. And men are unaware ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced today that ... on Thursday, October 30, 2008 at 1:45 p.m. PDT ... California., Steve Worland, Ph.D., President and Chief Executive ... an update on its development,programs., The presentation will ...
... KING OF PRUSSIA, Pa., Oct. 27 Universal,Health Services, ... net income was,$37.0 million, or $.73 per diluted share, ... 14% increase over the adjusted net,income per diluted share ... Net income was $152.9 million, or $3.00 per diluted ...
... ... BOSTON, Oct. 27 PAREXEL International,Corporation (Nasdaq: PRXL ... September 30, 2008., For the three months ended September ... compared with $208.1,million in the prior year period. The Company ...
Cached Medicine News:Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:Stress affects older adults more than young adults 2Health News:Psychological study reveals that red enhances men's attraction to women 2Health News:Psychological study reveals that red enhances men's attraction to women 3Health News:Anadys Pharmaceuticals to Present at Bio Investor Forum 2Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 2Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 3Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 4Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 5Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 6Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 7Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 8Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 9Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 10Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 11Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 12Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 13Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 14Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 15Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 16Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 17Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 18Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 19Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 20Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 2Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 3Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 4Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 5Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 6Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 7Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 8Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 9
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Bard® Channel Drain...
... Used for stone manipulation ... duct. The nitinol memory wire ... its shape following extreme torsion. ... the likelihood of mucosal damage ...
Used for serial post-operative cholangiography and the placement of a wire guide to facilitate post-operative E.R.C.P. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: